



Sheet 1 of 1

FORM PTO-249

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
JB01603K3 USSERIAL NO.:  
10/736,769INFORMATION DISCLOSURE STATEMENT  
FOR PATENT

(Use several sheets if necessary)

APPLICANT:  
Altmann *et al.*FILING DATE:  
December 16, 2003GROUP:  
To be assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						


## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
SWL	AC	WO 2004/32716 A2	Apr. 22, 2004	WIPO	A61B		
	AD						
	AE						
	AF						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


SWL	AG	Erickson <i>et al.</i> , "Studies on neuronal death in the mouse model of Niemann-Pick C disease." J. Neurosci. Res. 2002 Jun 15;68(6):738-44.					
	AH	Erickson <i>et al.</i> , "mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice." Mol. Reprod. Dev. 2002 Jun;62(2):167-73.					
	AI	Altmann <i>et al.</i> , "Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption." Science. 2004 Feb 20;303(5661):1201-4.					
	AJ	Erickson <i>et al.</i> , "Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice." J. Inherit. Metab. Dis. 2000 Feb;23(1):54-62.					
SWL	AK	International Search Report for International Application No. PCT/US03/40113.					
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						

4/11/06



Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FORM 149/PTO				ATTY. DOCKET NO.: JB01603K3 US		SERIAL NO.: 10/736,769	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE AS MANY SHEETS AS NECESSARY)				APPLICANT: Altmann <i>et al.</i>			
				FILING DATE: December 16, 2003		GROUP: 1645	
<b>DOMESTIC PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	CITE NO. <sup>1</sup>	DOCUMENT NUMBER	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
SWL		US 2004/0093629	05/13/04	Altmann <i>et al.</i>			
SWL		US 2004/0137467	07/15/04	Altmann <i>et al.</i>			
SWL		US 2004/0132058	07/08/04	Altmann <i>et al.</i>			
<b>FOREIGN PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	CITE NO. <sup>1</sup>	DOCUMENT Country code <sup>3</sup> - number <sup>4</sup> -kind code <sup>5</sup> (if known)	PUB. DATE.	NAME OF PATENTEE OR APPLICANT	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
Examiner signature: 				Date considered: 4/11/06			


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: JB01603K3 US	SERIAL NO.: 10/736,769
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Altmann <i>et al.</i>	
		FILING DATE: December 16, 2003	GROUP: 1645
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SWL		International Search Report for International Application NO. PCT/US03/22467	
		MGI web page "gene detail" of the NPC1L1 gene	
		Altmann et al., "Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption." Science. 2004 Feb 20;303(5661):1201-4.	
SWL		Davies et al., Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 2005 Apr 1;280(13):12710-20	
Examiner signature:		Date considered:	
		4/11/06	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


 OICE  
 MAY 18 2004


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: JB01603K3	SERIAL NO.: 10/736,769
<b>INFORMATION DISCLOSURE STATEMENT FOR PATENT</b> (Use several sheets if necessary)	APPLICANT: Altmann <i>et al.</i>	
	FILING DATE: December 16, 2003	GROUP: TO BE ASSIGNED

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SWL	AA	US RE37,721 E	05/28/02	Rosenblum <i>et al.</i>	514	210	
	AB	5,306,817	04/26/94	Thiruvengadam <i>et al.</i>	540	200	
	AC	5,561,227	10/01/96	Thiruvengadam <i>et al.</i>	540	200	
	AD	5,618,707	04/08/97	Homann <i>et al.</i>	435	146	
	AE	5,624,920	04/29/97	McKittrick <i>et al.</i>	514	210	
	AF	5,631,365	05/20/97	Rosenblum <i>et al.</i>	540	200	
	AG	5,656,624	08/12/97	Vaccaro <i>et al.</i>	540	210	
	AH	5,627,176	05/06/97	Kirkup <i>et al.</i>	514	210	
	AI	5,633,246	05/27/97	McKittrick <i>et al.</i>	514	210	
	AJ	5,661,145	08/26/97	Davis	514	210	
	AK	5,688,785	11/18/97	Vaccaro	514	210	
	AL	5,688,787	11/18/97	Burnett <i>et al.</i>	514	210	
	AM	5,688,990	11/18/97	Shankar	560	39	
	AN	5,698,548	12/16/97	Dugar <i>et al.</i>	514	210	
	AO	5,728,827	03/17/98	Thiruvengadam <i>et al.</i>	540	200	
	AP	5,739,321	04/14/98	Wu <i>et al.</i>	540	200	
	AQ	5,744,467	04/28/98	McKittrick <i>et al.</i>	514	210	
	AR	5,756,470	05/26/98	Yumibe <i>et al.</i>	514	25	
	AS	5,767,115	06/16/98	Rosenblum <i>et al.</i>	514	210	
	AT	5,846,966	12/08/98	Rosenblum <i>et al.</i>	514	210	
	AU	5,856,473	01/05/99	Shankar	540	200	
	AV	5,886,171	03/23/99	Wu <i>et al.</i>	540	200	
	AW	5,919,672	07/06/99	Homann <i>et al.</i>	435	121	
	AX	6,093,812	07/25/00	Thiruvengadam <i>et al.</i>	540	200	
	AY	6,096,883	08/01/00	Wu <i>et al.</i>	540	200	
	AZ	6,133,001	10/17/00	Homann <i>et al.</i>	435	121	
	BA	6,207,822	03/27/01	Thiruvengadam <i>et al.</i>	540	200	
	BB	6,627,757	09/30/03	Fu <i>et al.</i>	546	272.4	
	BC	6,632,933	10/14/03	Altmann <i>et al.</i>	536	17.4	
SWL	BD	6,593,078	07/15/03	Altmann <i>et al.</i>	435	4	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SWL	BE	WO 01/70974	09/27/01	WIPO	C12N	15/12	Abstr.	
SWL	BF	WO 01/57190	08/09/01	WIPO	C12N			


 4/11/06

SWL	BG	WO 03/100094	12/04/03	WIPO	C12Q	1/68		
	BH	WO 00/20623	04/13/00	WIPO	C12P	41/00		
	BI	WO 00/34240	06/15/00	WIPO	C07D	205/08		
	BJ	WO 00/60107	10/12/00	WIPO	C12P	17/10		
	BK	WO2004/014947 A1	02/19/04	WIPO	C07K	14/47		
	BL	WO 00/63703	10/26/00	WIPO	G01N	33/92		
	BM	WO 02/079174	10/10/02	WIPO	C07D	263/00		
	BN	WO 00/63703	10/26/00	WIPO	G01N	33/92		
SWL	BO	WO 01/75067	10/11/01	WIPO	C12N			
	BP							


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SWL	BQ	Minhas, "Current Progress in Lipid Therapy" Br. J. Cardiology 10(1): 59-68 (2003)
	BR	Abstracts 1-79 from "The International Conference on Niemann-Pick Type C Disease"; May 29-31, 2003; Tuscon, Arizona.
	BS	Carstea <i>et al.</i> , "Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis" Science 277:228-231 (1997).
	BT	Polypeptide Sequence ABG22693 disclosed in WO 01/75067.
	BU	Genbank Sequence Disclosure; Accession No. AF192522.
	BV	Genbank Sequence Disclosure; Accession No. AF002020.
	BW	Davies <i>et al.</i> , "Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1" Genomics 65(2): 137-145 (2000).
	BX	Ioannou <i>et al.</i> , "The structure and function of the Niemann-Pick C1 protein." Mol. Genet. Metab. 71(1-2): 175-181 (2000).
	BY	Genbank Sequence Disclosure, Accession No. AK078947.
	BZ	Altmann <i>et al.</i> , "The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption." Biochim. Biophys. ACTA 1580: 77-93 (2002).
	CA	DeNinno <i>et al.</i> , "Steroidal glycoside cholesterol absorption inhibitors" J. Med. Chem. 40(16):2547-2554 (1997).
	CB	Kramer, <i>et al.</i> , "Characterization and identification of the intestinal cholesterol uptake system" Falk Symposium 129, Bile Acids: From Genomics to Disease and Therapy, 147-160 (2003).
	CC	Amigo <i>et al.</i> , "Relevance of Niemann-Pick Type C1 Protein Expression in Controlling Plasma Cholesterol and Biliary Lipid Secretion in Mice" Hepatology 36(4): 819-828 (2002).
SWL	CD	Repa, <i>et al.</i> , "Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte". Journal of Lipid Research 43:1864-1874 (2002).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
SWL	CE	Hauser <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 37(51): 17843-17850 (1998).
	CF	Acton <i>et al.</i> , "Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor" <i>The Journal of Biological Chemistry</i> 269(33): 21003-21009 (1994).
	CG	Hernandez <i>et al.</i> , "Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter" <i>Biochimica et Biophysica Acta</i> 1486: 232-242 (2000).
	CH	Detmers <i>et al.</i> , "A target for cholesterol absorption inhibitors in the enterocyte brush border membrane" <i>Biochimica et Biophysica Acta</i> 1486: 243-252 (2000).
	CI	Smart <i>et al.</i> , "Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport" <i>Proc. Natl. Acad. Sci.</i> 101(10):3450-3455 (2004).
	CJ	Dawson <i>et al.</i> , "Intestinal cholesterol absorption" <i>Curr Opin Lipidol.</i> 10(4):315-320 (1999).
	CK	Allayee <i>et al.</i> , "Biochemistry. An absorbing study of cholesterol" <i>Biochemistry. An absorbing study of cholesterol.</i> <i>Science.</i> 290(5497):1709-1711 (2000).
	CL	Berge <i>et al.</i> , "Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters" <i>Science</i> 290(5497):1771-1775 (2000).
	CM	Jourdheuil-Rahmani <i>et al.</i> , "Biliary anionic peptide fraction and apoA-I regulate intestinal cholesterol uptake" <i>Biochem Biophys Res Commun</i> 292(2):390-5 (2002).
	CN	Werder <i>et al.</i> , "Role of scavenger receptors SR-BI and CD36 in selective sterol uptake in the small intestine" <i>Biochemistry</i> 40(38):11643-50 (2001).
SWL	CO	Zetia™ Prescribing Information Sheet.
	CP	
	CQ	
	CR	
	CS	
	CT	
	CU	
	CV	
	CW	
	CX	
EXAMINER		DATE CONSIDERED
		4/11/06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		